Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyCRDF +2.22%26 Equity-to-Asset is 0.71 as of Jun. 2026, which is 10% below its 10-year median of 0.79. GuruFocus rates CRDF with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 1,415 Biotechnology companies, Cardiff Oncology ranks better than 53.99% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cardiff Oncology's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $26.53 Mil. Cardiff Oncology's Total Assets for the quarter that ended in Jun. 2026 was $37.33 Mil.
Therefore, Cardiff Oncology's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.71.
The historical rank and industry rank for Cardiff Oncology's Equity-to-Asset or its related term are showing as below:
CRDF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28 Med: 0.79 Max: 0.97
Current: 0.71
During the past 13 years, the highest Equity to Asset Ratio of Cardiff Oncology was 0.97. The lowest was 0.28. And the median was 0.79.
CRDF's Equity-to-Asset is ranked better than 53.99% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs CRDF: 0.71
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cardiff Oncology Equity-to-Asset Related Terms
Cardiff Oncology Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRDF vs MNOV, PMVP, CING: Equity-to-Asset Comparison
For the Biotechnology subindustry, Cardiff Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cardiff Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a Equity-to-Asset of 0.71 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cardiff Oncology and its competitors. This is 10% below median its historical median of 0.79. Over the past decade, Cardiff Oncology's Equity-to-Asset has ranged from 0.28 to 0.97. According to the industry distribution chart, Cardiff Oncology ranks #651 out of 1415 companies in the Biotechnology industry, placing it in the top 46%.
Is Cardiff Oncology's Equity-to-Asset too high?
Cardiff Oncology's current Equity-to-Asset of 0.71 is 10% below median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.97. The Biotechnology industry median Equity-to-Asset is 0.68. Cardiff Oncology's value of 0.71 is 4.4% above this industry median. Based on the distribution chart, Cardiff Oncology ranks #651 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Equity-to-Asset compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #651 out of 1415 companies for Equity-to-Asset. This puts Cardiff Oncology in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Cardiff Oncology's value of 0.71 is 4.4% above this benchmark. Historically, Cardiff Oncology's own Equity-to-Asset has ranged from 0.28 to 0.97 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.68, Cardiff Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Equity-to-Asset of 0.71 is 4.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Equity-to-Asset is 0.71, which is 10% below median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current Equity-to-Asset of 0.71. The current Equity-to-Asset is 0.71, which is 10% below median its 10-year median of 0.79 and 4.4% above the Biotechnology industry median of 0.68. Cardiff Oncology's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Equity-to-Asset is 0.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
26GF Score
Get the complete analysis for CRDF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
